US2022023773A1PendingUtilityA1

Compositions comprising 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate

65
Individually held — no corporate assignee on recordPriority: Dec 10, 2018Filed: Dec 9, 2019Published: Jan 27, 2022
Est. expiryDec 10, 2038(~12.4 yrs left)· nominal 20-yr term from priority
Inventors:Douglas G. Metcalf
A61K 36/3482A61K 31/658C07D 311/80A61K 2236/55A61K 2236/39B01D 11/0488A61K 31/015A61K 2236/53C07C 37/72C07C 2601/16A61K 2236/331C07C 29/84B01D 11/0492A61K 2236/51B01D 9/0004A61K 31/05A61K 36/185A61K 31/352
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Various aspects of the disclosure relate to 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and compositions comprising 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A composition, comprising one or both of sodium ion (“Na+”) and potassium ion (“K+”); one or more of caffeine, thiamine, niacin, nicotinamide, riboflavin, pantothenate, sucrose, fructose, glucose, acesulfame, saccharin, stevioside, rebaudioside A, sucralose, tagatose, erythritol, maltitol, xylitol, mannitol, isomalt, and a mogroside; 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate; and 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol, wherein the composition comprises the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2- en-1-yl]-5-pentylbenzene-1,3-diol at a molar ratio of at least 1:10 and no greater than 10,000:1. 
     
     
         23 . The composition of  claim 22 , comprising the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol at a molar ratio of at least 1:1 and no greater than 100:1. 
     
     
         24 . The composition of  claim 22 , comprising xylitol. 
     
     
         25 . The composition of  claim 22 , comprising ethanol. 
     
     
         26 . The composition of  claim 22 , water. 
     
     
         27 . The composition of  claim 22 , comprising water at a concentration by weight of at least 50 percent and no greater than 99.99 percent. 
     
     
         28 . A composition, comprising potassium ion (“K+”); xylitol; 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate; and 2-[(1R, 6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. 
     
     
         29 . The composition of  claim 28 , comprising the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol at a molar ratio of at least 1:10 and no greater than 10,000:1. 
     
     
         30 . The composition of  claim 28 , comprising the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol at a molar ratio of at least 1:1 and no greater than 100:1. 
     
     
         31 . The composition of  claim 28 , comprising a solid phase, wherein the solid phase comprises a salt, and the salt comprises the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the potassium ion. 
     
     
         32 . The composition of  claim 28 , comprising ethanol. 
     
     
         33 . The composition of  claim 28 , comprising water. 
     
     
         34 . The composition of  claim 28 , comprising water at a concentration by weight of at least 50 percent and no greater than 99.99 percent. 
     
     
         35 . A composition, comprising sodium ion (“Na+”); xylitol; 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate; and 2-[(1R, 6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol. 
     
     
         36 . The composition of  claim 35 , comprising the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol at a molar ratio of at least 1:10 and no greater than 10,000:1. 
     
     
         37 . The composition of  claim 35 , comprising the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol at a molar ratio of at least 1:1 and no greater than 100:1. 
     
     
         38 . The composition of  claim 35 , comprising a solid phase, wherein the solid phase comprises a salt, and the salt comprises the 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-3-hydroxy-5-pentylphenolate and the sodium ion. 
     
     
         39 . The composition of  claim 35 , comprising ethanol. 
     
     
         40 . The composition of  claim 35 , comprising water. 
     
     
         41 . The composition of  claim 35 , comprising water at a concentration by weight of at least 50 percent and no greater than 99.99 percent.

Join the waitlist — get patent alerts

Track US2022023773A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.